Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2025 16:01 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
November 06, 2025 07:00 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week

Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
November 04, 2025 07:00 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in Four Upcoming Investor Conferences

Maze Therapeutics to Participate in Four Upcoming Investor Conferences
October 06, 2025 07:00 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

Maze Therapeutics appoints industry veteran Hervé Hoppenot as Chairman of the Board of Directors
September 11, 2025 07:35 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement

Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
September 11, 2025 07:30 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid...
September 02, 2025 07:00 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for...
August 12, 2025 16:01 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025 MZE829 Phase 2 HORIZON Trial Actively...
July 10, 2025 16:05 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in Two Upcoming Investor Conferences

Maze Therapeutics to Participate in Two Upcoming Investor Conferences
May 29, 2025 07:30 ET | Source: Maze Therapeutics, Inc.

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference

Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference